Computational Screening of Some Phytochemicals to Identify Best Modulators for Ligand Binding Domain of Estrogen Receptor Alpha
CONCLUSION: Additionally, these compounds are being reported for the first time in this study as possible inhibitors of ERα for treating breast cancer, according to the notion of drug repurposing. Hence, these phytochemicals can be further studied and used as a parent core molecule to develop innovative lead molecules for breast cancer therapy.PMID:38698754 | DOI:10.2174/0113816128287431240408045732 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - May 3, 2024 Category: Drugs & Pharmacology Authors: Veerachamy Alagarsamy P Shyam Sundar Viswas Raja Solomon Sankaranarayanan Murugesan Mohammed Muzaffar-Ur-Rehman Vishaka Sumant Kulkarni Mohaideen Thasthagir Sulthana Bandi Narendhar Govindraj Sabarees Source Type: research
Which Drugs are More Effective in Preventing Familial Adenomatous Polyposis Progression Based on Network Meta-Analysis?
CONCLUSION: The most effective treatment for reducing the number of colorectal polyps is celecoxib 16 mg/kg/day. On the other hand, a daily dosage of 2 g EPA-FFA demonstrates the best results in terms of decreasing colorectal polyp diameter.PMID:38698755 | DOI:10.2174/0113816128289465240422074745 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - May 3, 2024 Category: Drugs & Pharmacology Authors: Pei Luo Wenjun Shi Xianshuo Cheng Jun Yang Gen Pei Jian Dong Source Type: research
Nanoparticles as Drug Delivery Carrier-synthesis, Functionalization and Application
Curr Pharm Des. 2024 Apr 29. doi: 10.2174/0113816128304018240415095912. Online ahead of print.ABSTRACTIn recent years, advancements in chemistry have allowed the tailoring of materials at the nanoscopic level as needed. There are mainly four main types of nanomaterials used as drug carriers:metal-based nanomaterials, organic nanomaterials, inorganic nanomaterials, and polymer nanomaterials. The nanomaterials as a drug carrier showed advantages for decreased side effects with a higher therapeutic index. The stability of the drug compounds is increased by encapsulation of the drug within the nano-drug carriers, leading to de...
Source: Current Pharmaceutical Design - April 30, 2024 Category: Drugs & Pharmacology Authors: S Drishya Ramakrishna Prasad Are Prabhudutta Hota Anju R Babu Source Type: research
Ayurvedic and Chinese Herbs against Coronaviruses
Curr Pharm Des. 2024 Apr 29. doi: 10.2174/0113816128269864231112094917. Online ahead of print.ABSTRACTCOVID-19 is a viral disease that infects the lower airways, causing severe acute respiratory syndrome (SARS) and fatal pneumonia. The ripple effect of the COVID-19 outbreak has created serious problems in the healthcare systems of many countries and had far-reaching consequences for the global economy. Thus, effective control measures should be implemented for this coronavirus infection in the future. The ongoing episode of the SARS-CoV-2 sickness, COVID-19, in China, and the subsequent irregular spread of contamination to...
Source: Current Pharmaceutical Design - April 30, 2024 Category: Drugs & Pharmacology Authors: Amin Gasmi Sonia Kanwal Petro Oliinyk Roman Lysiuk Mariia Shanaida Asma Gasmi Benahmed Walallawita Kankanamge Tharindu Dushmantha Maria Arshad Ivanna Kernychna Larysa Lenchyk Taras Upyr Volodymyr Shanaida Geir Bj ørklund Source Type: research
Nanoparticles as Drug Delivery Carrier-synthesis, Functionalization and Application
Curr Pharm Des. 2024 Apr 29. doi: 10.2174/0113816128304018240415095912. Online ahead of print.ABSTRACTIn recent years, advancements in chemistry have allowed the tailoring of materials at the nanoscopic level as needed. There are mainly four main types of nanomaterials used as drug carriers:metal-based nanomaterials, organic nanomaterials, inorganic nanomaterials, and polymer nanomaterials. The nanomaterials as a drug carrier showed advantages for decreased side effects with a higher therapeutic index. The stability of the drug compounds is increased by encapsulation of the drug within the nano-drug carriers, leading to de...
Source: Current Pharmaceutical Design - April 30, 2024 Category: Drugs & Pharmacology Authors: S Drishya Ramakrishna Prasad Are Prabhudutta Hota Anju R Babu Source Type: research
Ayurvedic and Chinese Herbs against Coronaviruses
Curr Pharm Des. 2024 Apr 29. doi: 10.2174/0113816128269864231112094917. Online ahead of print.ABSTRACTCOVID-19 is a viral disease that infects the lower airways, causing severe acute respiratory syndrome (SARS) and fatal pneumonia. The ripple effect of the COVID-19 outbreak has created serious problems in the healthcare systems of many countries and had far-reaching consequences for the global economy. Thus, effective control measures should be implemented for this coronavirus infection in the future. The ongoing episode of the SARS-CoV-2 sickness, COVID-19, in China, and the subsequent irregular spread of contamination to...
Source: Current Pharmaceutical Design - April 30, 2024 Category: Drugs & Pharmacology Authors: Amin Gasmi Sonia Kanwal Petro Oliinyk Roman Lysiuk Mariia Shanaida Asma Gasmi Benahmed Walallawita Kankanamge Tharindu Dushmantha Maria Arshad Ivanna Kernychna Larysa Lenchyk Taras Upyr Volodymyr Shanaida Geir Bj ørklund Source Type: research
Nanoparticles as Drug Delivery Carrier-synthesis, Functionalization and Application
Curr Pharm Des. 2024 Apr 29. doi: 10.2174/0113816128304018240415095912. Online ahead of print.ABSTRACTIn recent years, advancements in chemistry have allowed the tailoring of materials at the nanoscopic level as needed. There are mainly four main types of nanomaterials used as drug carriers:metal-based nanomaterials, organic nanomaterials, inorganic nanomaterials, and polymer nanomaterials. The nanomaterials as a drug carrier showed advantages for decreased side effects with a higher therapeutic index. The stability of the drug compounds is increased by encapsulation of the drug within the nano-drug carriers, leading to de...
Source: Current Pharmaceutical Design - April 30, 2024 Category: Drugs & Pharmacology Authors: S Drishya Ramakrishna Prasad Are Prabhudutta Hota Anju R Babu Source Type: research
Ayurvedic and Chinese Herbs against Coronaviruses
Curr Pharm Des. 2024 Apr 29. doi: 10.2174/0113816128269864231112094917. Online ahead of print.ABSTRACTCOVID-19 is a viral disease that infects the lower airways, causing severe acute respiratory syndrome (SARS) and fatal pneumonia. The ripple effect of the COVID-19 outbreak has created serious problems in the healthcare systems of many countries and had far-reaching consequences for the global economy. Thus, effective control measures should be implemented for this coronavirus infection in the future. The ongoing episode of the SARS-CoV-2 sickness, COVID-19, in China, and the subsequent irregular spread of contamination to...
Source: Current Pharmaceutical Design - April 30, 2024 Category: Drugs & Pharmacology Authors: Amin Gasmi Sonia Kanwal Petro Oliinyk Roman Lysiuk Mariia Shanaida Asma Gasmi Benahmed Walallawita Kankanamge Tharindu Dushmantha Maria Arshad Ivanna Kernychna Larysa Lenchyk Taras Upyr Volodymyr Shanaida Geir Bj ørklund Source Type: research
Impact of Combination Therapy with Chemical Drugs and Megavoltage X-ray Exposure on Breast Cancer Stem Cells' Viability and Proliferation of MCF-7 and MDA-MB-231 Cell Lines
CONCLUSION: Anti-cancer and cytotoxic effects of metformin can be effective in this strategy. In conclusion, the combination of conventional chemotherapeutic drugs, including SB203580, metformin, and takinib with X-ray exposure can be a new approach to diminish the drug resistance of breast cancer.PMID:38676476 | DOI:10.2174/0113816128287325240329085055 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 27, 2024 Category: Drugs & Pharmacology Authors: Fatemeh Banisharif Dehkordi Mahdi Ghatrehsamani Maryam Abdolvand Amin Soltani Seyed Hossein Masoumi Source Type: research
Bear Bile Powder Improves Ulcerative Colitis by Protecting the Intestinal Mechanical Barrier and Regulating Intestinal Flora
CONCLUSION: Oral administration of a certain dose of BBP can significantly improve the symptoms of ulcerative colitis in mice. Part of the reason may be that it increases the expression of tight junction proteins, regulates specific flora in the intestine of mice, and maintains intestinal barrier homeostasis. In the future, the clinical application value of BBP will be explored, and BBP will be developed as a drug with the potential to treat UC and alleviate the pain of UC patients.PMID:38676524 | DOI:10.2174/0113816128294893240403074953 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 27, 2024 Category: Drugs & Pharmacology Authors: Zi-Bo Liu Xun Ye Chun-Jie Wu Da-Neng Wei Source Type: research
Comprehensive Overview of Innovative Strategies in Preventing Renal Ischemia-reperfusion Injury: Insights from Bibliometric and In Silico Analyses
CONCLUSION: The insights provided in this analysis will assist clinicians and researchers in selecting effective preventive approaches for renal IRI in surgical settings, potentially improving patient outcomes.PMID:38676525 | DOI:10.2174/0113816128283420240409050754 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 27, 2024 Category: Drugs & Pharmacology Authors: Myltykbay S Rysmakhanov Afshin Zare Aibolat S Smagulov Nurgul A Abenova Nadiar M Mussin Yerlan B Sultangereyev Bazylbek S Zhakiyev Gani K Kuttymuratov Mehmet Haberal Nazanin Jafari Hanieh Baneshi Shabnam Bakhshalizadeh Mahdi Mahdipour Farhad Rahmanifar Am Source Type: research
Impact of Combination Therapy with Chemical Drugs and Megavoltage X-ray Exposure on Breast Cancer Stem Cells' Viability and Proliferation of MCF-7 and MDA-MB-231 Cell Lines
CONCLUSION: Anti-cancer and cytotoxic effects of metformin can be effective in this strategy. In conclusion, the combination of conventional chemotherapeutic drugs, including SB203580, metformin, and takinib with X-ray exposure can be a new approach to diminish the drug resistance of breast cancer.PMID:38676476 | DOI:10.2174/0113816128287325240329085055 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 27, 2024 Category: Drugs & Pharmacology Authors: Fatemeh Banisharif Dehkordi Mahdi Ghatrehsamani Maryam Abdolvand Amin Soltani Seyed Hossein Masoumi Source Type: research
Bear Bile Powder Improves Ulcerative Colitis by Protecting the Intestinal Mechanical Barrier and Regulating Intestinal Flora
CONCLUSION: Oral administration of a certain dose of BBP can significantly improve the symptoms of ulcerative colitis in mice. Part of the reason may be that it increases the expression of tight junction proteins, regulates specific flora in the intestine of mice, and maintains intestinal barrier homeostasis. In the future, the clinical application value of BBP will be explored, and BBP will be developed as a drug with the potential to treat UC and alleviate the pain of UC patients.PMID:38676524 | DOI:10.2174/0113816128294893240403074953 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 27, 2024 Category: Drugs & Pharmacology Authors: Zi-Bo Liu Xun Ye Chun-Jie Wu Da-Neng Wei Source Type: research
Comprehensive Overview of Innovative Strategies in Preventing Renal Ischemia-reperfusion Injury: Insights from Bibliometric and In Silico Analyses
CONCLUSION: The insights provided in this analysis will assist clinicians and researchers in selecting effective preventive approaches for renal IRI in surgical settings, potentially improving patient outcomes.PMID:38676525 | DOI:10.2174/0113816128283420240409050754 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 27, 2024 Category: Drugs & Pharmacology Authors: Myltykbay S Rysmakhanov Afshin Zare Aibolat S Smagulov Nurgul A Abenova Nadiar M Mussin Yerlan B Sultangereyev Bazylbek S Zhakiyev Gani K Kuttymuratov Mehmet Haberal Nazanin Jafari Hanieh Baneshi Shabnam Bakhshalizadeh Mahdi Mahdipour Farhad Rahmanifar Am Source Type: research
Treatment of Pulmonary Embolism beyond Anticoagulation
Curr Pharm Des. 2024 Apr 24. doi: 10.2174/0113816128308493240418075258. Online ahead of print.NO ABSTRACTPMID:38659268 | DOI:10.2174/0113816128308493240418075258 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 25, 2024 Category: Drugs & Pharmacology Authors: Lampros Lakkas Christos S Katsouras Source Type: research
